Vitamin D: A novel therapeutic approach for keloid, an in vitro analysis

British Journal of Dermatology

Volumn 164, Issue 4, 2011, Pages 729-737

  Zhang, Guo You ^a,b   Cheng, T ^c   Luan, Q ^d   Liao, T ^e   Nie, C L ^f   Zheng, X ^a   Xie, X G ^a   Gao, W Y ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF LÜBECK   (Germany)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALCITRIOL; COLLAGEN; COLLAGEN TYPE 1; FIBRONECTIN; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLINE; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN D RECEPTOR;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; KELOID; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROSIS;

ADOLESCENT; ADULT; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; DIHYDROXYCHOLECALCIFEROLS; FEMALE; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOSORBENT TECHNIQUES; KELOID; MALE; PHENOTYPE; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1; VITAMINS; YOUNG ADULT;

EID: 79953711728     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10130.x     Document Type: Article

References (34)

1. Rockwell WB, Cohen IK, Ehrlick HP. Keloids and hypertrophic scars, a comprehensive review. Plast Reconstr Surg 1989; 84:827-37. (Pubitemid 19286117)
2. Kischer CW, Brody GS. Structure of the collagen nodule from hypertrophic scars and keloids. Scan Electron Microsc 1981; 3:371-6. (Pubitemid 11016022)
3. Uitto J, Perejda AJ, Abergel RP et al. Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts. Proc Natl Acad Sci U S A 1985; 82:5935-9. (Pubitemid 16218877)
4. Abergel RP, Pizzuro D, Meeker CA et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J Invest Dermatol 1985; 84:384-90. (Pubitemid 15056660)
5. Russell JD, Witt WS. Cell size and growth characteristics of cultured fibroblasts isolated from normal and keloid tissue. Plast Reconstr Surg 1976; 57:207-12.
6. Dusso AS, Brown AJ. Mechanism of vitamin D action and its regulation. Am J Kidney Dis 1998; 32:S13-24.
7. Li Y, Spataro BC, Yang J et al. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68:1500-10.
8. Artaza JN, Sirad F, Ferrini MG, Norris KC. 1,25(OH)2vitamin D3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cells. J Steroid Biochem Mol Biol 2010; 119:73-83.
9. Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 2009; 200:207-21.
10. Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene 2000; 246:9-21.
11. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17:3382-93. (Pubitemid 44865281)
12. Koleganova N, Piecha G, Ritz E, Gross ML. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 2009; 24:778-87.
13. Ramirez AM, Wongtrakool C, Welch T et al. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol 2010; 118:142-50.
14. Humbert PG, Dupond JL, Rochefort A et al. Localized scleroderma - response to 1,25-dihydroxyvitamin D3. Clin Exp Dermatol 1990; 15:396-8.
15. Hulshof MM, Pavel S, Breedveld FC et al. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994; 130:1290-3. (Pubitemid 24313289)
16. Hulshof MM, Bouwes Bavinck JN, Bergman W et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000; 43:1017-23.
17. Zhang GY, Yi CG, Li X et al. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. Br J Dermatol 2009; 160:762-70.
18. Essers J, Theil AF, Baldeyron C et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol 2005; 25:9350-9. (Pubitemid 41507836)
19. Naim R, Naumann A, Barnes J et al. Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture. Aesthetic Plast Surg 2008; 32:346-52.
20. Elst EF, Van Suijlekom-Smit LW, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 1999; 16:53-8. (Pubitemid 29102635)
21. Humbert P, Dupond JL, Agache P et al. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol 1993; 73:449-51. (Pubitemid 23351347)
22. Hullett DA, Laeseke PF, Malin G et al. Prevention of chronic allograft nephropathy with vitamin D. Transpl Int 2005; 18:1175-86. (Pubitemid 41726762)
23. Koshiishi I, Mitani H, Sumita T, Imanari T. 1,25-Dihydroxyvitamin D(3) prevents the conversion of adipose tissue into fibrous tissue in skin exposed to chronic UV irradiation. Toxicol Appl Pharmacol 2001; 173:99-104.
24. Szalay G, Sauter M, Haberland M et al. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res 2009; 104:851-9.
25. Siller-López F, Sandoval A, Salgado S et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004; 126:1122-33. (Pubitemid 38451183)
26. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17:253-8. (Pubitemid 350087694)
27. Tuan TL, Zhu JY, Sun B et al. Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts. J Invest Dermatol 1996; 106:1007-11. (Pubitemid 26153504)
28. Zhang GY, Yi CG, Li X et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res 2008; 300:177-84.
29. Panichi V, Migliori M, Taccola D et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001; 60:87-95.
30. Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 1990; 282:164-7. (Pubitemid 20155219)
31. Yanagisawa J, Yanagi Y, Masuhiro Y et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283:1317-21.
32. Subramaniam N, Leong GM, Cock TA et al. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001; 276:15741-6.
33. Hus-Citharel A, Marchetti J, Corvol P, Llorens-Cortes C. Potentiation of [Ca2+]i response to angiotensin III by cAMP in cortical thick ascending limb. Kidney Int 2002; 61:1996-2005. (Pubitemid 34539317)
34. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73:288-94. (Pubitemid 32109858)